Linked e-resources
Details
Table of Contents
Intro; Preface; Testimonials; Contents; About the Authors; 1: Innovation: Key to Success in the Pharmaceutical Industry; 1.1 The Productivity Paradox; 1.2 The Blockbuster Imperative; Entering the Market Quickly; 1.3 High Risks in Drug Development; Differentiation via Clinical Profiles; 1.4 Outlook; 2: The Industry Challenge: Who Would Want to Be in This Business?; 2.1 A Highly Complex Industry; Industry Classification and Background; Extensive Product Groups; 2.2 Five Forces Analysis of the Drug Industry; Force 1: Bargaining Power of Suppliers; Force 2: Bargaining Power of Buyers
Force 3: Risk of Entry from Potential CompetitorsForce 4: Threat of Substitute Products; Force 5: Rivalry Among Established Companies; Force 6: The Regulators; RandD Regulations; Price Regulations and National Healthcare Systems; Intellectual Property Rights; 2.3 Pressure on the Traditional Pharma Business Model; Continued Rise of Generics/Branded Generics Products; Relevance of Specialty Pharma Drugs; Pressure on Portfolio Optimization; Increasingly Competitive Marketing Efforts; Legal Challenges; 2.4 Growth Drivers for the Years to Come; 2.5 Seeking Salvation in MandA and Diversification
Case in Point: Mergermania Around Actavis/AllerganMotivations for Pharma MandA; Growth Through Diversification; 2.6 Conclusions; 3: The Science and Technology Challenge: How to Find New Drugs; 3.1 Rise of the Biotechnology Industry: Boosting Innovation; 3.2 The Challenge of Target Discovery; 3.3 High-Throughput Screening: Fail Earlier, Succeed Sooner; Combinatorial Chemistry: Cut Experimental Cycle Times; Hit and Lead Generation Technologies Beyond HTS; 3.4 The Bioinformatics and eHealthcare Revolution; ``Big Data`` and Its Relevance for Pharmaceutical RandD
3.5 Proteomics and the `-omics ́World3.6 Pharmacogenetics and Pharmacogenomics; 3.7 Computer-Based Drug Discovery; 3.8 Conclusions; 4: The Pipeline Challenge: How to Organize Innovation; 4.1 The Relevance of Pipeline Management; Complexity and Phases of the RandD Process; 4.2 Phases and Checkpoints in the Pharma RandD Process; Case-in-Point: Risk Assessment of a Drug Candidate: Pantoprazole; Stage-Gate and Portfolio Management; 4.3 Portfolio Analysis; Application of a Financial Evaluation of a Project: The Case of Biotech; 4.4 Portfolio Management
Portfolio Decision-Making at Merck Serono S.A.4.5 Conclusions; 5: The Make-or-Buy Challenge: How to In- and Outsource Innovation; 5.1 The Disaggregation of the Pharma Value Chain; 5.2 Outsourcing of Pharmaceutical RandD; Outsourcing Strategy: Captive Offshoring at ALTANA Pharma; AJ Biologics: Successful Partnering of a Vaccine Start-Up; Contract Research Organizations (CROs); Strategic CRO Partners of Pfizer; Managing Outsourcing Activities at Solvias; 5.3 Strategic Research Partnerships; 5.4 In-licensing: Enhancing the Innovation Pipeline; 5.5 Co-development: Benefiting from Joint Resources
Force 3: Risk of Entry from Potential CompetitorsForce 4: Threat of Substitute Products; Force 5: Rivalry Among Established Companies; Force 6: The Regulators; RandD Regulations; Price Regulations and National Healthcare Systems; Intellectual Property Rights; 2.3 Pressure on the Traditional Pharma Business Model; Continued Rise of Generics/Branded Generics Products; Relevance of Specialty Pharma Drugs; Pressure on Portfolio Optimization; Increasingly Competitive Marketing Efforts; Legal Challenges; 2.4 Growth Drivers for the Years to Come; 2.5 Seeking Salvation in MandA and Diversification
Case in Point: Mergermania Around Actavis/AllerganMotivations for Pharma MandA; Growth Through Diversification; 2.6 Conclusions; 3: The Science and Technology Challenge: How to Find New Drugs; 3.1 Rise of the Biotechnology Industry: Boosting Innovation; 3.2 The Challenge of Target Discovery; 3.3 High-Throughput Screening: Fail Earlier, Succeed Sooner; Combinatorial Chemistry: Cut Experimental Cycle Times; Hit and Lead Generation Technologies Beyond HTS; 3.4 The Bioinformatics and eHealthcare Revolution; ``Big Data`` and Its Relevance for Pharmaceutical RandD
3.5 Proteomics and the `-omics ́World3.6 Pharmacogenetics and Pharmacogenomics; 3.7 Computer-Based Drug Discovery; 3.8 Conclusions; 4: The Pipeline Challenge: How to Organize Innovation; 4.1 The Relevance of Pipeline Management; Complexity and Phases of the RandD Process; 4.2 Phases and Checkpoints in the Pharma RandD Process; Case-in-Point: Risk Assessment of a Drug Candidate: Pantoprazole; Stage-Gate and Portfolio Management; 4.3 Portfolio Analysis; Application of a Financial Evaluation of a Project: The Case of Biotech; 4.4 Portfolio Management
Portfolio Decision-Making at Merck Serono S.A.4.5 Conclusions; 5: The Make-or-Buy Challenge: How to In- and Outsource Innovation; 5.1 The Disaggregation of the Pharma Value Chain; 5.2 Outsourcing of Pharmaceutical RandD; Outsourcing Strategy: Captive Offshoring at ALTANA Pharma; AJ Biologics: Successful Partnering of a Vaccine Start-Up; Contract Research Organizations (CROs); Strategic CRO Partners of Pfizer; Managing Outsourcing Activities at Solvias; 5.3 Strategic Research Partnerships; 5.4 In-licensing: Enhancing the Innovation Pipeline; 5.5 Co-development: Benefiting from Joint Resources